Rocuronium

# rocuronium ## Overview - **Classification**: Non-depolarizing neuromuscular blocker (NDNMB), aminosteroidal - **Mechanism**: Competitively binds to nicotinic cholinergic receptors at the motor end-plate, blocking acetylcholine action and preventing muscle contraction. ## Primary Indications 1. **Facilitation of Tracheal Intubation**: For routine and rapid sequence intubation (RSI). 2. **Skeletal Muscle Relaxation**: During surgical procedures. 3. **Facilitation of Mechanical Ventilation**: In critically ill patients. ## Adult Dosing ### Standard Dosing **Tracheal Intubation (Routine)** - **Dose**: **0.6 mg/kg** ideal body weight - **Frequency**: Single dose - **Route**: IV push - **Duration**: Effect lasts ~30-60 minutes **Tracheal Intubation (Rapid Sequence Intubation - RSI)** - **Dose**: **0.9-1.2 mg/kg** ideal body weight - **Frequency**: Single dose - **Route**: IV push - **Onset**: Within 60 seconds **Maintenance of Neuromuscular Blockade** - **Dose**: **0.1-0.2 mg/kg** ideal body weight (IV bolus) OR **4-16 mcg/kg/min** (continuous IV infusion) - **Frequency**: As needed, guided by neuromuscular monitoring (e.g., train-of-four, TOF) - **Route**: IV bolus or continuous IV infusion ### Dose Adjustments - **Renal Impairment**: No specific initial dose adjustment needed. May have slightly prolonged duration of action. Monitor closely. - **Hepatic Impairment**: Metabolism and excretion significantly prolonged. Consider lower initial dose (**0.3 mg/kg**) and longer dosing intervals. - **Elderly Patients**: No routine initial dose adjustment. May have prolonged duration of action; monitor closely. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **0.6 mg/kg** - **Frequency**: Single dose for intubation - **Maximum**: Do not exceed **0.6 mg/kg** - **Special Notes**: Onset is slower (up to 2 minutes) and duration of action is significantly prolonged compared to older children/adults. Use with caution. ### Infants (1-12 months) - **Dose**: **0.6 mg/kg** (for intubation) - **Frequency**: Single dose - **Maximum**: Do not exceed **0.6 mg/kg** (initial) - **Special Notes**: Onset and duration are similar to children 1-12 years, generally faster than neonates. ### Children (1-12 years) - **Dose**: **0.6-1.2 mg/kg** (for intubation, 1.2 mg/kg for RSI) - **Frequency**: Single dose - **Maximum**: Do not exceed **1.2 mg/kg** (initial) - **Special Notes**: May have a slightly faster onset and shorter duration than adults, especially with higher doses. ### Adolescents (13-18 years) - **Dose**: Adult dosing guidelines apply. - **Maximum**: Adult doses, e.g., **1.2 mg/kg** for RSI. ## Safety Information ### Contraindications - **Absolute**: Known hypersensitivity to rocuronium or bromide. - **Absolute**: Patients with known hypersensitivity to other aminosteroid neuromuscular blockers. ### Common Adverse Effects - **Very Common (>10%)**: None - **Common (1-10%)**: Transient hypotension, hypertension, tachycardia, injection site pain. - **Serious but Rare**: Anaphylaxis/anaphylactoid reactions (can be severe, life-threatening), prolonged neuromuscular blockade. ### Key Drug Interactions - **Inhalation Anesthetics (e.g., isoflurane, sevoflurane)**: Potentiate and prolong neuromuscular blockade. Reduce rocuronium maintenance doses. - **Aminoglycosides (e.g., gentamicin, amikacin)**: Enhance neuromuscular blockade. - **Calcium Channel Blockers (e.g., verapamil, diltiazem)**: May enhance neuromuscular blockade. - **Corticosteroids (chronic use)**: May lead to steroid-induced myopathy when used with NMBAs, leading to prolonged weakness. - **Magnesium Sulfate**: Potentiates neuromuscular blockade. ## Monitoring & Follow-up - **Before Treatment**: Assess baseline vital signs, electrolytes, renal and hepatic function. - **During Treatment**: - **Neuromuscular function**: Monitor with train-of-four (TOF) stimulation using a peripheral nerve stimulator to guide dosing. - **Vital Signs**: Continuous monitoring (HR, BP, SpO2). - **Airway/Ventilation**: Ensure patent airway and adequate mechanical ventilation. - **Sedation/Analgesia**: Ensure adequate sedation and analgesia as rocuronium has no analgesic or sedative properties. - **Clinical Signs**: Watch for signs of inadequate blockade (patient movement, bucking ventilator) or prolonged blockade (residual paralysis after discontinuation). ## Clinical Pearls - 💡 **Reversal**: Reversible by Sugammadex for rapid and complete reversal, or by cholinesterase inhibitors (e.g., neostigmine) for partial reversal, especially after recovery of 1-2 twitches. - 💡 **No Analgesic/Sedative Effect**: Always ensure adequate sedation and analgesia as patients remain fully conscious but paralyzed. - 💡 **Malignant Hyperthermia**: Rocuronium is **not** a known trigger for Malignant Hyperthermia. - 💡 **Refrigeration**: Store in refrigerator (2-8°C). Protect from light. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.